| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Heilongjiang ZBD Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.13 |
| 52 Week High | CN¥17.87 |
| 52 Week Low | CN¥8.89 |
| Beta | 0.35 |
| 1 Month Change | 4.51% |
| 3 Month Change | -0.09% |
| 1 Year Change | -31.08% |
| 3 Year Change | -25.20% |
| 5 Year Change | -15.87% |
| Change since IPO | -34.49% |
Recent News & Updates
Shareholder Returns
| 603567 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 4.3% | 0.8% | -0.4% |
| 1Y | -31.1% | -13.4% | -14.4% |
Return vs Industry: 603567 underperformed the CN Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: 603567 underperformed the CN Market which returned -14.4% over the past year.
Price Volatility
| 603567 volatility | |
|---|---|
| 603567 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 603567 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603567's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 2,760 | n/a | www.zbdzy.com |
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Heilongjiang ZBD Pharmaceutical Co., Ltd. Fundamentals Summary
| 603567 fundamental statistics | |
|---|---|
| Market cap | CN¥10.46b |
| Earnings (TTM) | CN¥507.81m |
| Revenue (TTM) | CN¥4.33b |
20.6x
P/E Ratio2.4x
P/S RatioIs 603567 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603567 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.33b |
| Cost of Revenue | CN¥3.35b |
| Gross Profit | CN¥980.13m |
| Other Expenses | CN¥472.32m |
| Earnings | CN¥507.81m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 22.64% |
| Net Profit Margin | 11.73% |
| Debt/Equity Ratio | 40.3% |
How did 603567 perform over the long term?
See historical performance and comparison